We are live on ! Find out more
DNA icon

Ginkgo Bioworks

165 hedge funds and large institutions have $375M invested in Ginkgo Bioworks in 2025 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more call options, than puts

Call options by funds: $22.1M | Put options by funds: $9.64M

105% more capital invested

Capital invested by funds: $183M → $375M (+$192M)

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

35% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 34

3% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 35

0.76% more ownership

Funds ownership: 71.16%71.93% (+0.76%)

0% more funds holding

Funds holding: 165165 (0)

Holders
165
Holders Change
Holders Change %
0%
% of All Funds
2.17%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.07%
New
36
Increased
46
Reduced
34
Closed
35
Calls
$22.1M
Puts
$9.64M
Net Calls
+$12.5M
Net Calls Change
+$10.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Viking Global Investors
1
Viking Global Investors
Connecticut
$40.2M
Baillie Gifford & Co
2
Baillie Gifford & Co
United Kingdom
$36.9M -$580K -74,840 -2%
BlackRock
3
BlackRock
New York
$34.3M +$14M +1,808,161 +146%
Vanguard Group
4
Vanguard Group
Pennsylvania
$26.8M +$1.94M +250,118 +12%
EAM
5
Erste Asset Management
Austria
$22.5M +$2.71M +350,000 +21%
ACG
6
Anchorage Capital Group
New York
$19.6M
Legal & General Group
7
Legal & General Group
United Kingdom
$16.8M +$557K +71,927 +5%
Millennium Management
8
Millennium Management
New York
$15.2M -$565K -72,983 -5%
Bank of America
9
Bank of America
North Carolina
$13.6M +$1.55M +199,813 +20%
Goldman Sachs
10
Goldman Sachs
New York
$12.9M +$3.53M +456,032 +66%
JMFC
11
J.M. Forbes & Co
Massachusetts
$12.1M -$134K -17,323 -2%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$10.5M +$3.71M +479,154 +105%
PGCM
13
Prescott Group Capital Management
Oklahoma
$8.73M +$3.18M +409,851 +112%
State Street
14
State Street
Massachusetts
$8.34M +$3.14M +405,682 +121%
SIAU
15
SB Investment Advisers (UK)
United Kingdom
$6.87M
Morgan Stanley
16
Morgan Stanley
New York
$5.73M -$978K -126,186 -20%
OM
17
Opaleye Management
Massachusetts
$5.63M -$5.38M -695,000 -58%
National Bank of Canada
18
National Bank of Canada
Quebec, Canada
$5.56M +$3.83M +493,900 New
JF
19
Jump Financial
Illinois
$4.16M +$2.87M +370,038 New
Charles Schwab
20
Charles Schwab
California
$3.73M +$762K +98,389 +42%
Ensign Peak Advisors
21
Ensign Peak Advisors
Utah
$3.72M +$34.9K +4,500 +1%
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$3.62M -$1.11M -143,031 -31%
Northern Trust
23
Northern Trust
Illinois
$3.59M +$1.69M +217,817 +215%
UBS Group
24
UBS Group
Switzerland
$3.51M +$227K +29,340 +10%
ETC
25
Exchange Traded Concepts
Oklahoma
$3.32M -$127K -16,359 -5%

DNA Hedge Fund Activity: Q2 2025 in Review

165 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q2 2025, worth a combined $375M — up 105% from $183M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new DNA positions and 35 closed out — a net gain of 1 holder — while 46 added to existing stakes and 34 trimmed.

The largest buyer was BlackRock, adding an estimated $14M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.34M sold.

  • 165 institutional investors held Ginkgo Bioworks (DNA) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $375M of Ginkgo Bioworks stock for Q2 2025, up 105% quarter-over-quarter.
  • 36 funds opened new Ginkgo Bioworks positions in Q2 2025 and 35 closed out, a net change of +1 holder.
  • The largest Ginkgo Bioworks buyer in Q2 2025 was BlackRock, an estimated $14M added.
  • The largest Ginkgo Bioworks seller in Q2 2025 was EcoR1 Capital, an estimated $8.34M sold.

Based on aggregated 13F filings for Q2 2025.